NCT06797986 - A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects with HPV Positive HNSCC. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions

Head and Neck Squamous Cell Carcinoma (HNSCC)HPV (human Papillomavirus)-Associated CarcinomaHPV Positive Oropharyngeal Squamous Cell Carcinoma

Interventions

BIOLOGICAL

BVAC-E6E7 (low level)

BVAC-E6E7 is an immunotherapeutic vaccine designed to treat unresectable recurrent or metastatic head and neck squamous cell carcinoma positive to HPV 16 or 18.

BIOLOGICAL

BVAC-E6E7 (high level)

BVAC-E6E7 is an immunotherapeutic vaccine designed to treat unresectable recurrent or metastatic head and neck squamous cell carcinoma positive to HPV 16 or 18.

BIOLOGICAL

BVAC-E6E7 (RP2D)

BVAC-E6E7 is an immunotherapeutic vaccine designed to treat unresectable recurrent or metastatic head and neck squamous cell carcinoma positive to HPV 16 or 18.

All Listed Sponsors

lead

Cellid Co., Ltd.

INDUSTRY